Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results

Biomea Fusion, Inc. (NASDAQ:BMEA) earns a place on our list of the top 10 stocks under $5 that could triple.

Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results

As of March 19, 2026, almost 88% of covering analysts keep bullish ratings on the stock. With a consensus price target of $6.00, indicating a potential upside of 415.02%, analyst sentiment remains positive toward Biomea Fusion, Inc. (NASDAQ:BMEA).

On March 14, 2026, Biomea Fusion, Inc. (NASDAQ:BMEA) reported positive 52-week follow-up findings from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes at the ATTD conference in Barcelona. This clinical progress serves as the foundation for analyst optimism.

Of the 267 patients assessed in the randomized, placebo-controlled trial, 163 completed at least 80% of their dosage before a clinical hold. The findings showed statistically significant declines in HbA1c, with severe insulin-deficient individuals experiencing reductions of up to 1.50% at Week 52. Efficacy was further supported by improvements in beta-cell activity and long-lasting glucose control nine months after therapy. There were no significant side effects or treatment-related discontinuations, and the therapy was well tolerated.

Biomea Fusion, Inc. (NASDAQ:BMEA) formulates covalent small-molecule therapeutics aimed at treating cancers and metabolic disorders, with its primary candidate, icovamenib, targeting diabetes and BMF-219 addressing oncogenic signaling in genetically characterized tumors.

While we acknowledge the risk and potential of BMEA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMEA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.